In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics-Reference-Cited by-同舟云学术

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Published:2001-04 Issue:3 Volume:11 Page:223-235
ISSN:0960-314X
Container-title:Pharmacogenetics
language:en
Short-container-title:Pharmacogenetics

Author:

Tang Cuyue,Shou Magang,Rushmore Thomas H.,Mei Qin,Sandhu Punam,Woolf Eric J.,Rose Mark J.,Gelmann Alyssa,Greenberg Howard E.,De Lepeleire Inge,Van Hecken Anne,De Schepper Paul J.,Ebel David L.,Schwartz Jules I.,Rodrigues A. David

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Pharmacology, Toxicology and Pharmaceutics,Genetics

Reference58 articles.

1. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

2. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide

3. Genetic factors influencing the metabolism of tolbutamide

4. Allelic and functional variability of cytochrome P4502C9

5. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359allele as low-Kmcatalysts of cyclophosphamide and ifosfamide activation

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes;Archives of Pharmacal Research;2023-12

2. Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome <i>P450 2C9*3</i> Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database;Biological and Pharmaceutical Bulletin;2023-06-01

3. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients;Acta Pharmaceutica Sinica B;2023-01

4. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism;Archives of Pharmacal Research;2022-05

5. Genetic variations and epigenetic modulations in CYP genes: Implications in NSAID-treatment of arthritis patients;The Nucleus;2021-09-27